Yahoo
XETRA - Delayed Quote EUR

Stratec SE (SBS.DE)

22.50 -0.25 (-1.10%)
At close: October 30 at 5:35:18 PM GMT+1
Chart Range Bar
Loading chart for SBS.DE
  • Previous Close 22.75
  • Open 22.90
  • Bid 22.55 x 3600
  • Ask 22.75 x 6200
  • Day's Range 22.40 - 23.10
  • 52 Week Range 16.30 - 26.55
  • Volume 18,827
  • Avg. Volume 11,887
  • Market Cap (intraday) 273.509M
  • Beta (5Y Monthly) 0.85
  • PE Ratio (TTM) --
  • EPS (TTM) -0.03
  • Earnings Date Nov 12, 2026
  • Forward Dividend & Yield 0.60 (2.62%)
  • Ex-Dividend Date Jun 24, 2026
  • 1y Target Est 25.80

Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.

www.stratec.com

1,383

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

SBS.DE
3.69%
DAX P (^GDAXI)
5.42%

1-Year Return

SBS.DE
3.00%
DAX P (^GDAXI)
7.05%

3-Year Return

SBS.DE
42.51%
DAX P (^GDAXI)
75.44%

5-Year Return

SBS.DE
82.08%
DAX P (^GDAXI)
64.56%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY25
Revenue 58.23M
Earnings --
Profit Margin 0.00%

Q1

FY24

Q2

FY24

Q1

FY25

Q2

FY25

0
20M
40M
60M
0.0%

Analyst Insights

View More

Analyst Price Targets

21.00
25.80 Average
22.50 Current
37.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.16%

  • Return on Assets (ttm)

    2.52%

  • Return on Equity (ttm)

    -0.17%

  • Revenue (ttm)

    244.81M

  • Net Income Avi to Common (ttm)

    -395k

  • Diluted EPS (ttm)

    -0.03

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.03M

  • Total Debt/Equity (mrq)

    48.53%

  • Levered Free Cash Flow (ttm)

    13.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: